Author: Yueping Li; Zhiwei Xie; Weiyin Lin; Weiping Cai; Chunyan Wen; Yujuan Guan; Xiaoneng Mo; Jian Wang; Yaping Wang; Ping Peng; Xudan Chen; Wenxin Hong; Guangming Xiao; Jinxin Liu; Lieguang Zhang; Fengyu Hu; Feng Li; Feng Li; Fuchun Zhang; Xilong Deng; Linghua Li
Title: An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) Document date: 2020_3_23
ID: 9hknw4ws_46
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.19.20038984 doi: medRxiv preprint 1 2 1 in Shanghai observed 134 patients with COVID-19 and did not find any effects of LPV/r and arbidol on relieving symptoms or accelerating virus clearance after treatment for 5 days [20] . Despite the small sample size, our study also suggests that monotherapy of LPV/r or arbidol might not improve the .....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.19.20038984 doi: medRxiv preprint 1 2 1 in Shanghai observed 134 patients with COVID-19 and did not find any effects of LPV/r and arbidol on relieving symptoms or accelerating virus clearance after treatment for 5 days [20] . Despite the small sample size, our study also suggests that monotherapy of LPV/r or arbidol might not improve the clinical outcome in treating with mild/moderate COVID-19.
Search related documents:
Co phrase search for related documents- clinical outcome and mild moderate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clinical outcome and sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- clinical outcome and small sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- clinical outcome and virus clearance: 1, 2, 3, 4, 5, 6
- mild moderate and sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
- mild moderate and small sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- mild moderate and virus clearance: 1, 2, 3, 4, 5, 6, 7
- sample size and small sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86
Co phrase search for related documents, hyperlinks ordered by date